How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?
Main Authors: | Alessandro Loglio, Pietro Lampertico |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2020-01-01
|
Series: | Hepatology Communications |
Online Access: | https://doi.org/10.1002/hep4.1476 |
Similar Items
-
Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies
by: Elisabetta Degasperi, et al.
Published: (2022-10-01) -
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
by: Anna S. Lok, et al.
Published: (2020-01-01) -
The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights
by: Fabrizio Fabrizi, et al.
Published: (2023-02-01) -
Current Trend in Antiviral Therapy for Chronic Hepatitis B
by: Rong-Nan Chien, et al.
Published: (2022-02-01) -
Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment
by: Lisa Sandmann, et al.
Published: (2024-02-01)